CLASS G AUTOANTIBODIES TO OXIDATIVELY MODIFIED LOW DENSITY LIPOPROTEIN IN TYPE 2 DIABETES MELLITUS PATIENTS WHO HAVE HAD NON-Q-MYOCARDIAL INFARCTION | Zendy

Н. В. Алтуніна | Zendy; V. G. Lizogub | Zendy; O. N. Bondarchuk | Zendy

Open Access

CLASS G AUTOANTIBODIES TO OXIDATIVELY MODIFIED LOW DENSITY LIPOPROTEIN IN TYPE 2 DIABETES MELLITUS PATIENTS WHO HAVE HAD NON-Q-MYOCARDIAL INFARCTION

Author(s) -

Н. В. Алтуніна,

V. G. Lizogub,

O. N. Bondarchuk

Publication year - 2021

Publication title -

problems of endocrine pathology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.141

H-Index - 2

eISSN - 2518-1432

pISSN - 2227-4782

DOI - 10.21856/j-pep.2015.3.01

Subject(s) - autoantibody , medicine , diabetes mellitus , endocrinology , type 2 diabetes mellitus , insulin resistance , low density lipoprotein , lipoprotein , myocardial infarction , type 2 diabetes , concomitant , insulin , cholesterol , immunology , antibody

The article presents the results of a study of class G autoantibodies to oxidatively modified low-density lipoprotein (ox-LDL) in patients with type 2 diabetes mellitus which have had non-Qmyocardial infarction and their connection with disturbances of carbohydrate and lipid metabolism, the levels of cytokines. It was identified the decrease level of IgG to ox-LDL in the serum of these patients compared with the control group and patients without diabetes. The study found that with increasing degree of insulin resistance, the concentration of class G autoantibodies to ox-LDL in diabetic postinfarction patients was reduced. It was also revealed their direct connection with the level of anti-inflammatory IL-10. The data obtained may be evidence of the negative impact of carbohydrate metabolism disorders on the level of IgG autoantibodies to ox-LDL and the data may refer to their protective role in type 2 diabetes mellitus with concomitant atherosclerosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research